Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) Delivered Via a SelfDose (TM) Device in the Treatment of Subjects With Moderate to Severe Plaque-Type Psoriasis
Sponsor: Janssen Research & Development, LLC
Listed as NCT02905331, this PHASE3 trial focuses on Psoriasis and remains completed. Sponsored by Janssen Research & Development, LLC, it has been updated 14 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 9 earlier versions
-
Oct 2018 — Nov 2018 [monthly]
Completed PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Apr 2017 — May 2017 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Apr 2017 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .